Skip to content
Menu

Citigroup Maintains Buy on Summit Therapeutics, Lowers Price Target to $42

Benzinga Newsdesk 14 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and lowers the price target from $43 to $42.

Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and lowers the price target from $43 to $42.

Read at benzinga.com